Victhom

Cramer's Stop Trading! JP Morgan's Secondary a Bit Too Expensive (6/2/09)

www.cnbc.com/id/31091877

Jim look at Nomura analyst call....

Cramer's Stop Trading! JP Morgan's Secondary a Bit Too Expensive (6/2/09)

Wednesday June 3, 02:51 PM
Qatar fund says remains supportive of Barclays
DUBAI, June 3 (Reuters) - Qatar Holding, a division of sovereign wealth fund Qatar Investment Authority, on Wednesday said it remained a supportive shareholder in UK bank Barclays (LSE: BARC.L - news) .

'Qatar Holding remains a supportive shareholder in Barclays, which it regards as a world class bank, led by a board of directors and a professional managment team for which it maintains the utmost respect,' said Ahmad Al-Sayed, managing director and CEO, in a statement.

The statement comes one day after an Abu Dhabi fund sold more than 11 percent of Barclays.

'Qatar Holding, moreover, regards Barclays as a valued commercial and strategic partner particularly in the Middle East markets and expects to build on this fruitful relationship over the long term,' according to the statement, which was read by a spokesman for the holding company.

(Reporting by Thomas Atkins; Editing by Jason Benham) Keywords: BARCLAYS QATAR/

Cramer's Stop Trading! JP Morgan's Secondary a Bit Too Expensive (6/2/09)

Hey Jim.....Barclays (BCS) trades at P/E of 4.83
you said sell in march at $2.75 I bought 25000 shares sold them at $21 this monday....I made a killing with your call....and now....

I'm buying back BCS again on your downgrade thanks again....Jim...you make my life easier...and Barclays will sell BGI division $12B by June 18 and restart dividend in Q3...when JPM at PE of 20 after much more "DILLUTION" will pay dividend???

Barclays May Sell BGI for as Much as $12 Billion, WSJ Reports

By Dan Hart

May 16 (Bloomberg) -- Barclays Plc, the U.K.’s third- biggest bank, is in talks to sell its asset management unit for as much as $12 billion, with BlackRock Inc. among interested bidders, the Wall Street Journal said, citing unidentified people familiar with the matter.

The business includes the exchange-traded funds unit iShares, which Barclays agreed to sell to CVC Capital Partners Ltd. for $4.4 billion two months ago, the newspaper said.

The iShares and securities-lending units each generate as much as a third of the profit for the Barclays Global Investors subsidiary, the newspaper said, citing a person familiar with the situation. BGI had a pretax profit of 595 million pounds ($903 million) in 2008, the Journal said.

Barclays does not comment on speculative stories, a company spokeswoman in London said when contacted by Bloomberg today.

To contact the reporter on this story: Dan Hart in Washington at [e-mail]

Cramer's Mad Money - Will Pfizer Buy Allergan? (12/3/08)

HEY JIM....You should tell your reader to read this instead....They will make more money with Pfizer than Allergan...LOL (buy LOW PFE is better than High Allergan?? right??)

Ben Graham Would Buy Pfizer, Tiffany, Grant’s Says By Eric Martin

Dec. 10 (Bloomberg) -- Pfizer Inc. and Tiffany & Co. are among eight stocks that Benjamin Graham, the father of value investing and Warren Buffett’s mentor, would buy, Grant’s Interest Rate Observer said.

Cooper Industries Inc., Nucor Corp., Cintas Corp., Archer Daniels Midland Co., Molex Inc. and RadioShack Corp. also meet the seven criteria Graham presented in 1973 for stocks that a “defensive investors might buy with confidence,” according to the latest issue of Grant’s, which was released today.

“That there are as many as eight is a notable fact,” the newsletter said. “In March 2003, near what would prove to be the bottom of the post-Nasdaq washout, Grant’s could identify only two that met the grade.”

Graham favored companies that have “adequate size;” current assets that exceed liabilities by two times; 10 straight years of profit; 20 years of uninterrupted dividends; 10 years of earnings growth exceeding 33 percent; a price-to-earnings ratio of less than 15; and a price-to-book ratio that’s less than 1.5, according to Grant’s, an investment newsletter founded by James Grant in 1983.

“Security Analysis,” published in 1934, provided a road map for value investors including Buffett, the chairman of Berkshire Hathaway Inc.

An equal-weighted index of the eight companies Grant’s identified has surged 32 percent since Nov. 20, the day the Standard & Poor’s 500 Index dropped to an 11-year low.

To contact the reporter on this story: Eric Martin in New York at [e-mail]...

Last Updated: December 10, 2008 18:14 EST

Cramer's Mad Money - Will Pfizer Buy Allergan? (12/3/08)

PFE will be better off continue internal R&D like ELI LILLY or Merck....Wait the market collapse to buy the best biotech at less than PE of 10...like Celgene is still not cheap...Amgen too...look at BMy trading at PE of 13 after Citigroup said BMY is a buy with target of $25...PFE on the other hand trade at 6.95 PE with dividend yield at 8%

Common Cramer...don't you know that Pfizer quit Ophtalmology...to concentrate of Rhumatoid...with Phase III with $4.5B product in pipeline also..25 in Phase III...with over 100 in phase I-II-III with $26B of Cash.....PFE can't be very patient.....because lots of Biotech trade still at PE of 25....like CELGENE...LOL

PFIZER going to stem cells and will soon sell lots of generic too like MRK...LILLY...etc...